Table 1 Summary of genotypic, metabolic and cardiovascular data of patients with CGL (n = 10)
Case Gender/age Pubertal stage | Subtype mutation (gene) | Comorbidities, microvascular complications | Drugs | LVMI (g/m2.7) cIMT (mm) cQT (s)a | CAN LVH |
|---|---|---|---|---|---|
1 ♀, 7 years M2P2 | Type 2 CGL BSCL2 | High HOMA-IR score, ↓HDL, ↑TG, nephropathy (moderate albuminuria), ↑BP | MTF | 63.9 0.61 0.43 | Clinical LVH |
2 ♀, 7 years M2P2 | Type 1 CGL AGPAT2 | High HOMA-IR score, ↓HDL, ↑TG | None | 32.8 0.66 0.45a | Absent No LVH |
3 ♂, 9 years G1P1 | DNA Not available | High HOMA-IR score, ↓HDL, ↑TG | None | 36.2 0.57 0.41 | Absent No LVH |
4 ♀, 10 years M2P2 | Type 2 CGL BSCL2 | DM, high HOMA-IR score, ↓HDL, ↑TG | MTF | 44.5 0.53 0.41 | Clinical No LVH |
5 ♂, 10 years G2P1 | Type 2 CGL BSCL2 | DM, ↓HDL, ↑TG, ↑cholesterol, nephropathy (severe albuminuria) | MTF, insulin | 29.9 0.54 0.44a | Absent No LVH |
6 ♂, 14 years G4P4 | DNA Not available | DM, ↓HDL, ↑TG, ↑cholesterol | MTF | 37.8 0.54 0.45a | Absent No LVH |
7 ♀, 14 years M4P4 | Type 2 CGL BSCL2 | DM, ↓HDL, ↑TG, ↑cholesterol, nephropathy (severe albuminuria), peripheral neuropathy, ↑BP | MTF, acarbose, insulin, ciprofibrate | 88.7 0.75 0.49a | Clinical LVH |
8 ♂, 14 years G5P5 | Type 2 CGL BSCL2 | DM, high HOMA-IR score, ↓HDL, ↑TG, nephropathy (moderate albuminuria) | MTF | 65.3 0.57 0.41 | Absent LVH |
9 ♀, 25 years M5P5 | Type 1 CGL AGPAT2 | DM, ↓HDL, ↑TG, ↑cholesterol, ↑BP, nephropathy (severe albuminuria), peripheral neuropathy | MTF, insulin, ciprofibrate | 154.0* 0.64 0.47a | Clinical/ Advanced LVH |
10 ♀, 30 years M5P5 | DNA Not available | DM, ↓HDL-c, ↑TG, ↑BP, nephropathy (severe albuminuria) | MTF, insulin, losartan | 88.6* 0.60 0.42 | Incipient No LVH |